Trial record 1 of 1 for:    Estrogen Use in Protection from Cognitive Decline
Previous Study | Return to List | Next Study

Estrogen Use in Protection From Cognitive Decline

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Natalie Rasgon, Stanford University
ClinicalTrials.gov Identifier:
NCT00097058
First received: November 17, 2004
Last updated: May 14, 2014
Last verified: June 2012
  Purpose

This study is designed to assess the effects of estrogen therapy among postmenopausal women at risk for cognitive decline.


Condition
Aging
Menopause

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Estrogen Use in Protection From Cognitive Decline

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Changes in cognition and brain metabolism [ Time Frame: Baseline and 24 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

whole blood serum urine


Estimated Enrollment: 71
Study Start Date: August 2003
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Continue current hormone therapy
2
Taper off hormone therapy

Detailed Description:

A total of 71 postmenopausal women ages 50-65 on estrogen therapy will be randomized to continue or discontinue use of estrogen and will be followed for two years.

Participants will undergo PET and MRI scans and neuropsychological assessments initially and at the end of the two-year follow-up period. These procedures will allow us to evaluate brain metabolism and cognitive performance at baseline and two years following continuation or discontinuation of estrogen therapy.

We hypothesize that women who discontinue estrogen will show more evidence of decline than those who continue estrogen. This project will expand current knowledge of effects of estrogen by 1) determining whether estrogen use among postmenopausal women at risk for cognitive decline is protective of brain metabolism, 2) identifying early predictors for cognitive decline, and 3) developing guidelines for estrogen use in postmenopausal women.

  Eligibility

Ages Eligible for Study:   45 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Women between the ages of 45 and 65 years of age, currently on estrogen therapy for 1 year prior to enrollment in study, and at risk for cognitive decline.

Criteria

Inclusion Criteria:

  • Women between the ages of 45 and 65
  • Currently on hormone replacement
  • One year or more post complete cessation of menses
  • Willing to sign the Human Subject Protection Consent form prior to enrollment in the study
  • Willing to be randomized to continue or discontinue estrogen therapy
  • Adequately visually and auditorially acute to allow neuropsychological testing
  • Beyond 8 years of educational achievement to allow adequate neuropsychological testing
  • Willing to undergo brain imaging
  • At risk for cognitive decline, as defined by one or more of the following: Personal or family history of mood disorder, Hypothyroidism, Diabetes, Family history of Alzheimer's, APOE-4 allele

Exclusion Criteria:

  • Diagnosis of possible or probable Alzheimer's disease or dementia
  • Cerebrovascular disease or uncontrolled hypertension (systolic BP >170 or diastolic BP >100)
  • History of myocardial infarction within previous year or unstable heart disease
  • History of significant liver disease, pulmonary disease, or current cancer
  • Contraindication for MRI (metal in body, claustrophobia, etc.)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00097058

Locations
United States, California
Stanford University School of Medicine, Dept. of Psychiatry and Behavioral Sciences
Stanford, California, United States, 94070-5723
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Natalie Rasgon, MD, PhD Stanford University School of Medicine, Dept of Psychiatry and Behavioral Sciences
Principal Investigator: Terence Ketter, MD Stanford University
Principal Investigator: Jerome Yesavage, MD Stanford University
Principal Investigator: Jennifer Hoblyn, MD VA Palo Alto Health Care System
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Natalie Rasgon, Principal Investigator, Stanford University
ClinicalTrials.gov Identifier: NCT00097058     History of Changes
Obsolete Identifiers: NCT00238589
Other Study ID Numbers: IA0063, R01AG022008, SPO #29004, Grant #R01 AG022008
Study First Received: November 17, 2004
Last Updated: May 14, 2014
Health Authority: United States: Federal Government

Keywords provided by Stanford University:
Aging
Menopause
Estrogen Replacement Therapy
Cognitive Decline

Additional relevant MeSH terms:
Cognition Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 23, 2014